A Study to Learn if the Study Medicines Called Itraconazole and Cyclosporine Change How the Body Processes the Other Study Medicine Called Danuglipron in Healthy Adults
This research is an early-stage study, sometimes called a Phase I trial. We want to understand how two existing medicines, itraconazole and cyclosporine, might affect how your body processes a new medicine called Danuglipron. Danuglipron is being developed for conditions like Type 2 diabetes and obesity. By studying these interactions in healthy adults, scientists can learn more about how to use Danuglipron safely and effectively in the future. This type of study mainly focuses on understanding drug interactions rather than directly treating a condition, and involves careful monitoring of how the medicines are handled by the body.
At a glance
What is this study about?
This study is an important early step in developing new medicines. It’s a “human pharmacology” study, which means researchers are keenly interested in understanding how specific medicines behave inside the human body. In this particular study, they want to see if two commonly used medicines – itraconazole (often used for fungal infections) and cyclosporine (used to prevent organ rejection or for immune system conditions) – change the way a new medicine called Danuglipron is processed by the body. Danuglipron is currently being researched as a potential treatment for conditions like Type 2 diabetes and obesity.
The main goal is to understand if taking itraconazole or cyclosporine at the same time as Danuglipron makes Danuglipron stay in the body longer, get removed more quickly, or reach higher or lower levels than expected. This kind of information is crucial for doctors and scientists to know how to safely prescribe and dose new medicines in the future, especially if patients might be taking other medications at the same time.
By taking part, healthy volunteers help gather vital information. This helps researchers understand if different combinations of medicines are safe and effective. It's not about treating a specific disease in this study, but about gathering fundamental knowledge that will benefit many patients in the future who might need these medications.
Key takeaways
- This study explores how Danuglipron, a new medicine for diabetes and obesity, interacts with two other common drugs.
- It's an early-stage study (Phase I) focusing on understanding drug interactions in the body.
- The study is for healthy adults, not for treating any specific illnesses.
- Participants will take study medicines and attend regular clinic visits for monitoring.
- Your contribution helps gain vital knowledge for future patient care.
- You can stop participating at any time.
Who may be eligible?
To join this study, you need to be an adult, aged 18 or older. Researchers welcome both men and women to take part.
You should also be generally healthy. This means that if you have any ongoing serious medical conditions, or take certain regular medications, you might not be suitable. The study is specifically looking for healthy volunteers to understand how the medicines interact without other health issues complicating the results.
Full details about who can and cannot join will be discussed with you by the study team. They will ask questions about your health and any medicines you take to make sure the study is a safe and good fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy, without serious ongoing medical conditions?
- Are you willing to take study medications and attend several clinic visits?
- Are you comfortable with blood tests and other routine medical checks?
- Are you able to understand and follow study instructions carefully?
What does participation involve?
If you decide to take part, you will be given specific study medicines, including itraconazole, cyclosporine, and Danuglipron, one or more times. The study team will explain exactly which medicines and how often. You'll have regular visits to the clinic where nurses or doctors will perform assessments. These might include blood tests, urine tests, checking your blood pressure and heart rate, and asking you about how you are feeling. The purpose of these tests is to see how your body is reacting to the medicines and how the medicines are being processed.
You will need to follow instructions carefully about when and how to take the medicines, and what you can and cannot eat or drink before certain appointments. The total time you'll be involved in the study, including all visits and follow-ups, will be clearly explained to you before you agree to participate.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is Danuglipron?
Danuglipron is a new medicine being studied for conditions like Type 2 diabetes and obesity. This study aims to understand how it interacts with other medicines.
Why is this study only for healthy adults?
By studying healthy adults, researchers can understand how the medicines interact without other health issues making the results unclear. This helps them learn basic information about the drugs.
Will I get treated for diabetes or obesity in this study?
No, this study is not about treating your condition. It’s an early-stage study to understand how medicines interact in generally healthy people, so you won't receive treatment for specific illnesses.
What does 'Human Pharmacology (Phase I)' mean?
This is an early stage of research where scientists learn how a new medicine works in the body and its common side effects. It's often done with a small group of healthy volunteers.
Do I have to pay to join the study?
No, you don't have to pay. In many studies, travel expenses and sometimes compensation for your time are provided.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.